Home
|
Contact Us
|
Sitemap
Overview
Management Team
Board of Directors
Scientific Advisory Board
Careers
Current Openings
Benefits
About Pathogen Inactivation
Conventional Blood Testing
International Consensus Conference on Pathogen Inactivation
Glossary of Terms
How INTERCEPT Works
Product Pipeline
Commercializing The INTERCEPT System
The INTERCEPT Blood System
Case Study
Abstracts
Archived Abstracts
Publications
Archived Publications
Investor Overview
Corporate Governance
Analyst Coverage
Press Releases
Investor Events
Webcasts
Annual Reports
Annual Meeting
Stock Information
SEC Filings
Information Request
Investor Contacts
RSS Feeds
Global Links
Management Team
Investors
Investor Overview
Corporate Governance
Analyst Coverage
Press Releases
Investor Events
Webcasts
Annual Reports
Annual Meeting
Stock Information
SEC Filings
Information Request
Investor Contacts
RSS Feeds
Investor Overview
Corporate Governance
Analyst Coverage
Press Releases
Investor Events
Webcasts
Annual Reports
Annual Meeting
Stock Information
SEC Filings
Information Request
Investor Contacts
RSS Feeds
Press Releases
Normal
Press Release RSS
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
Date
Subject
October 22, 1997
October 22, 1997
Cerus Corporation Announces Third Quarter Results
October 8, 1997
October 8, 1997
Cerus Milestone Triggers Equity Investment and $750,000 Payment from Baxter Healthcare
July 22, 1997
July 22, 1997
Cerus Corporation Announces Second Quarter Results
July 8, 1997
July 8, 1997
Cerus Study Shows Gamma Irradiation Can be Combined with Its Proprietary Pathogen Inactivation System for Platelets
May 23, 1997
May 23, 1997
Cerus Cleared by the FDA to Commence Pilot Patient Study for its Platelet Pathogen Inactivation System
April 27, 1997
April 27, 1997
Cerus Corporation Reports Technology for Inactivating Infectious Pathogens in Platelet Concentrates in Transfusion
April 24, 1997
April 24, 1997
Cerus Corporation Announces First Quarter Results
April 11, 1997
April 11, 1997
Cerus Commences Phase I Clinical Trial of its Plasma Pathogen Inactivation System
January 31, 1997
January 31, 1997
Cerus Corporation Makes Initial Public Offering of Common Stock
© 2012 Cerus Corporation
Legal
|
Privacy
Powered By Q4 Web Systems
3.5.18.3156